LIXT Stock Catalyst: Lixte Biotechnology Closes $5.0 Million Private Placement

Lixte Biotechnology Holdings, Inc. (XNAS: LIXT) announced on July 02, 2025, the closing of a private placement with accredited investors. The placement involved the purchase and sale of approximately $5.0 million of shares of Common Stock (or Pre-Funded Warrants), Series B Convertible Preferred Stock, and Common Warrants.

The private placement included 2,382,084 shares of Common Stock (or Pre-Funded Warrants), 3,573,130 shares of Series B Convertible Preferred Stock, and 6,355,214 Common Warrants. The transaction consisted of $4.0 million in Common Stock and $1.0 million in Series B Convertible Preferred Stock.

As of the latest data, Lixte Biotechnology has a free float of 5,693,200 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.